Marker Story

<div class='circular--portrait' style='background:#4682B4;color: #f8f8f8;font-size:4em;'>MT</div>
MRKR -- USA Stock  

USD 2.13  0.06  2.74%

The next fiscal quarter end is expected on the 31st of March 2021. The stock is currently experiencing an active upward rally. Marker Therapeutics Book Value per Share is relatively stable at the moment as compared to the past year. Marker Therapeutics reported last year Book Value per Share of 0.58. As of 03/19/2021, Current Ratio is likely to grow to 5.69, while Earnings before Tax are likely to drop (31 M). As many millenniums are trying to avoid healthcare space, it makes sense to sum up Marker Therapeutics a little further and try to understand its current market patterns. I will address a few possible reasons retail investors do not currently respect this stock.
Published over three weeks ago
View all stories for Marker Therapeutics | View All Stories
Should I sell my Marker (NASDAQ:MRKR) holdings?
This firm currently holds 12.26 M in liabilities with Debt to Equity (D/E) ratio of 0.45, which is about average as compared to similar companies.
Marker Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 1.6253, which conveys a somewhat significant risk relative to the market. Let's try to break down what Marker's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Marker Therapeutics will likely underperform. Although it is vital to follow Marker Therapeutics price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. Our philosophy towards estimating future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Marker Therapeutics expected return of 1.08 will be sustainable into the future, we have found twenty-seven different technical indicators, which can help you to check if the expected returns are sustainable. Use Marker Therapeutics value at risk, as well as the relationship between the skewness and day median price to analyze future returns on Marker Therapeutics.
Marker Therapeutics financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Marker Therapeutics, including all of Marker Therapeutics's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Marker Therapeutics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Marker Therapeutics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Understanding Marker Total Liabilities

Marker Therapeutics liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Marker Therapeutics has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Marker Therapeutics balance sheet include debt obligations and money owed to different Marker Therapeutics vendors, workers, and loan providers. Below is the chart of Marker short long-term liabilities accounts currently reported on its balance sheet.
You can use Marker Therapeutics financial leverage analysis tool to get a better grip on understanding its financial position

How important is Marker Therapeutics's Liquidity

Marker Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Marker Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Marker Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Marker Therapeutics's total debt and its cash.

A Deeper Perspective On Marker Therapeutics

The company reported the previous year's revenue of 466.79 K. Net Loss for the year was (28.71 M) with loss before overhead, payroll, taxes, and interest of (18.41 M).

Asset Breakdown

22.9 M
Assets Non Current
22.6 M
Current Assets
Total Assets49.22 Million
Current Assets22.63 Million
Assets Non Current22.88 Million

Over 3 percent spike for Marker Therapeutics. What does it mean for retail investors?

Latest standard deviation is at 8.35. Marker Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Marker Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Marker Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Marker Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Marker Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on Marker Therapeutics

While few other entities under the biotechnology industry are still a bit expensive, Marker Therapeutics may offer a potential longer-term growth to retail investors. To conclude, as of the 19th of March 2021, we believe that at this point, Marker Therapeutics is dangerous with very high odds of financial distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our primary 30 days advice on the enterprise is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Marker Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com